UCHL5 and cancer: A compelling aspect of this model is the synergy expected by targetingan alternative enzymatic function in the proteasome, and a recent publicationindicated RA190 to be synergistic with bortezomib and carfilzomib39.Our findings merged with this published result suggest that inhibition of Uch37 maybe effective towards restricting cancer cell proliferation with synergy towardscurrently FDA (Food and Drug Administration)-approved proteasome inhibitors.